# Prasinezumab (PASADENA / related)

Source: https://onco.cc/trials/da-trial-prasinezumab/  
OnCo record `da-trial-prasinezumab` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Prasinezumab was studied in early Parkinson’s disease as an anti-alpha-synuclein antibody. It is not a dementia approval.

## Summary

Kept as a cited synuclein programme neighbour for Lewy-body biology on this atlas. Parkinson’s results do not equal a dementia label.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Registry id: NCT03100149
- Phase: 2
- Setting: Early Parkinson’s disease
- Sponsor: Roche

## Sources

- ClinicalTrials.gov NCT03100149: https://clinicaltrials.gov/study/NCT03100149

## Connected records

- diagnoses: [Parkinson’s disease dementia](https://onco.cc/diagnoses/parkinsons-disease-dementia/)
- drugs: [Prasinezumab](https://onco.cc/drugs/da-prasinezumab/)
- companies: [Roche](https://onco.cc/companies/da-roche/)

---
JSON: https://onco.cc/api/v1/entities/da-trial-prasinezumab.json